Straits Times Index
3,107.09 -23.15 (-0.74%) S&P 500
3,585.62 -54.85 (-1.51%) Dow
28,725.51 -500.09 (-1.71%) Nasdaq
10,575.62 -161.88 (-1.51%) BTC-USD
19,196.88 +73.89 (+0.39%) CMC Crypto 200
436.43 -7.00 (-1.58%)
Pfizer Inc. (PFE)
Pre-market:
| Previous close | 44.16 |
| Open | 44.17 |
| Bid | 43.66 x 3200 |
| Ask | 43.92 x 2200 |
| Day's range | 43.73 - 44.60 |
| 52-week range | 40.94 - 61.71 |
| Volume | |
| Avg. volume | 17,660,841 |
| Market cap | 245.596B |
| Beta (5Y monthly) | 0.65 |
| PE ratio (TTM) | 8.51 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 1.60 (3.66%) |
| Ex-dividend date | 03 Nov 2022 |
| 1y target est | N/A |
- Business Wire
Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age
NEW YORK & MAINZ, Germany, September 26, 2022--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the U.S. Food and Drug Administration (FDA) requesting Emergency Use Authorization (EUA) of a 10-µg booster dose of the companies’ Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for children ages 5 through 11 years of age. The request for Emergency Use Authorization of the Omicron BA.4/BA.5-adapted bivalent vaccine in this age group is sup
- Business Wire
Pfizer Declares Fourth-Quarter 2022 Dividend
NEW YORK, September 22, 2022--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.40 fourth-quarter 2022 dividend on the company’s common stock, payable December 5, 2022, to holders of the Common Stock of record at the close of business on November 4, 2022. The fourth-quarter 2022 cash dividend will be the 336th consecutive quarterly dividend paid by Pfizer.
- Business Wire
Pfizer to Supply Global Fund Up to 6 Million PAXLOVID™ Treatment Courses for Low-and-Middle-Income Countries
NEW YORK, September 22, 2022--Pfizer Inc. (NYSE: PFE) announced today an agreement to supply up to six million treatment courses of its COVID-19 oral treatment, PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) to Global Fund as part of its COVID-19 Response Mechanism (C19RM). The C19RM has been the primary channel for providing grant support to low- and middle-income countries to purchase COVID-19 tests, treatments, personal protective equipment and critical elements of healt
